Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

Rhea-AI Summary

Pharvaris (PHVS) has announced multiple presentations of clinical data for deucrictibant at three major medical conferences in May-June 2025. The presentations will take place at the 14th C1-Inhibitor Deficiency and Angioedema Workshop in Budapest, the 2025 Eastern Allergy Conference in Palm Beach, and the EAACI Congress 2025 in Glasgow. Key presentations focus on deucrictibant's long-term safety and efficacy data from the CHAPTER-1 and RAPIDe-2 extension studies for both prophylaxis and treatment of hereditary angioedema (HAE) attacks. Notable topics include biomarker data, quality of life improvements, pharmacokinetics of the XR tablet formulation, and the CHAPTER-3 Phase 3 trial design. The company will make all presentation materials available on their investor relations website.

Insights

Pharmaceutical Clinical Trial Expert

Pharvaris presenting promising late-stage deucrictibant data from multiple trials in hereditary angioedema, showing sustained efficacy and favorable safety profile.

The upcoming data presentations for deucrictibant across three scientific congresses represent significant clinical progress for Pharvaris' lead candidate. Most notably, they'll present long-term safety and efficacy data from two important extension studies: CHAPTER-1 (prophylaxis) and RAPIDe-2 (on-demand treatment). These extension studies provide crucial insights into durability of response which isn't captured in shorter pivotal trials.

The CHAPTER-1 extension data specifically shows that deucrictibant not only prevents HAE attacks but also improves health-related quality of life and disease control - endpoints that matter tremendously to patients with this debilitating condition. Similarly, the RAPIDe-2 extension confirms sustained efficacy for acute attack treatment, including for potentially life-threatening upper airway and laryngeal attacks.

The pharmacokinetic data for the extended-release (XR) tablet formulation demonstrating sustained therapeutic exposure with once-daily dosing is particularly important, as convenient dosing drives patient compliance in chronic conditions like HAE. This XR formulation is being evaluated in their Phase 3 CHAPTER-3 trial, whose design will also be presented.

The novel biomarker assay presentations suggest Pharvaris is developing companion diagnostic capabilities to better identify and monitor patients with bradykinin-mediated angioedema, potentially expanding their addressable market beyond HAE to include acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The epidemiology data on bradykinin-mediated angioedema will help quantify this expanded opportunity in Europe.

Collectively, these presentations paint a picture of a comprehensive development program with both prophylactic and on-demand treatment options, convenient oral dosing, long-term safety, and efforts to expand their addressable patient population with biomarker-guided approaches.

ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14^th C1-Inhibitor Deficiency and Angioedema Workshop, to be held from May 29-June 1, 2025, in Budapest; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025, in Palm Beach, Fl.; and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, to be held from June 13-16, 2025, in Glasgow.

Details of the presentations are as follows:
C1-Inhibitor Deficiency and Angioedema Workshop, Budapest, May 29-June 1, 2025.

• Title: Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin-Mediated Angioedema in Prospective and Biobank Plasma Samples
  Presenter: Evangelia Pardali, Ph.D.
  Format: Oral Presentation, O-02
  Date, time: Friday, May 30, 8:45-9:00 CEST (2:45-3:00 a.m. ET)
• Title: Long-Term Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life and Disease Control in Participants With Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study
  Presenter: Markus Magerl, M.D.
  Format: Poster Presentation, P-19
  Date, time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
• Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant XR Tablet for Prophylaxis of Hereditary Angioedema Attacks: Results of a Pharmacokinetics Study in Healthy Volunteers
  Presenter: Zhi-Yi Zhang, Ph.D.
  Format: Poster Presentation, P-20
  Date, time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
• Title: Acquired Angioedema Due to C1-Inhibitor Deficiency: Patient Experience and Assessment of Patient-Reported Outcome Measures
  Presenter: Andrea Zanichelli, M.D., Ph.D.
  Format: Poster Presentation, P-17
  Date, time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
  Presenter: Emel Aygören-Pürsün, M.D.
  Format: Oral Presentation, O-33
  Date, time: Saturday, May 31, 15:30-15:45 CEST (9:30-9:45 a.m. ET)
• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
  Presenter: Marc A. Riedl, M.D., M.S.
  Format: Oral Presentation, O-34
  Date, time: Saturday, May 31, 15:45-16:00 CEST (9:45-10:00 a.m. ET)
• Title: Durability Of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
  Presenter: Anna Valerieva, M.D., Ph.D.
  Format: Poster Presentation, P-56
  Date, time: Saturday, May 31, 16:45-17:45 CEST (10:45-11:45 a.m. ET)
• Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
  Presenter: Andrea Zanichelli, M.D., Ph.D.
  Format: Poster Presentation, P-42
  Date, time: Saturday, May 31, 16:45-17:45 CEST (10:45-11:45 a.m. ET)
• Title: Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study
  Presenter: Ramón Lleonart, M.D.
  Format: Poster Presentation, P-55
  Date, time: Saturday, May 31, 16:15-17:45 CEST (10:15-11:45 a.m. ET)
• Title: Epidemiology of Bradykinin-Mediated Angioedema in the European Population
  Presenter: Emel Aygören-Pürsün, M.D.
  Format: Poster Presentation, P-30
  Date, time: Saturday, May 31, 16:15-17:45 CEST (10:15-11:45 a.m. ET)
  
  

2025 Eastern Allergy Conference, Palm Beach, Fl., May 29-June 1, 2025.

• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
  Presenter: John Anderson, M.D.
  Format: Poster Presentation
  Date, time: Friday, May 30, 9:45-11:00 a.m. ET
• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
  Presenter: John Anderson, M.D.
  Format: Poster Presentation
  Date, time: Friday, May 30, 9:45-11:00 a.m. ET
  
  

EAACI Congress 2025, Glasgow, June 13-16, 2025.

• Title: Clinical Validation of a Novel Kinin Biomarker Assay for Characterization of Bradykinin-Mediated Pathologies in U.S. Subjects with Hereditary Angioedema
  Presenter: Evangelia Pardali, Ph.D.
  Format: Flash Talk (e-Poster), Abstract #000949, FT03
  Date, time: Friday, June 13, 13:15-14:45 BST (8:15-9:45 a.m. ET)
• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
  Presenter: Emel Aygören-Pürsün, M.D.
  Format: Thematic Poster Session (e-Poster and Poster Session) Abstract #000070
  Date, time: Saturday, June 14, 12:00-13:00 BST (7:00-8:00 a.m. ET)
• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
  Presenter: Henriette Farkas, M.D., Ph.D., D.Sc.
  Format: Thematic Poster Session (e-Poster and Poster Session), Abstract #000069
  Date, time: Saturday, June 14, 12:00-13:00 BST (7:00-8:00 a.m. ET)
• Title: Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema due to C1 Inhibitor Deficiency
  Presenter: Andrea Zanichelli, M.D., Ph.D.
  Format: Thematic Poster Session (e-Poster and Poster Session), Abstract #000331
  Date, time: Sunday, June 15, 12:45-13:45 BST (7:45-8:45 a.m. ET)
• Title: Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study
  Presenter: Anna Valerieva, M.D., Ph.D.
  Format: Flash Talk (e-Poster), Abstract #000076, FT16
  Date, time: Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)
• Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
  Presenter: William Lumry, M.D.
  Format: Flash Talk (e-Poster), Abstract #000068, FT16
  Date, time: Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)
• Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema in the CHAPTER-1 Open-Label Extension Study
  Presenter: Markus Magerl, M.D.
  Format: Flash Talk (e-Poster), Abstract #000075, FT16
  Date, time: Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)
• Title: Health-Related Quality of Life and Clinical Characteristics in People Living with Hereditary Angioedema Prescribed Long Term Prophylaxis Alone and On-Demand Treatment Alone
  Presenter: Laurence Bouillet, M.D., Ph.D.
  Format: Oral Presentation, Abstract #000044, OAS18
  Date, time: Sunday, June 15, 15:45-17:15 BST (10:45 a.m.-12:15 p.m. ET)

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.

Contact
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

FAQ

What clinical data will PHVS present at the upcoming medical conferences in 2025?

Pharvaris will present data on deucrictibant, including long-term safety and efficacy results from CHAPTER-1 and RAPIDe-2 extension studies, biomarker data, quality of life improvements, and CHAPTER-3 Phase 3 trial design at three conferences: C1-Inhibitor Workshop in Budapest, Eastern Allergy Conference in Florida, and EAACI Congress in Glasgow.

When and where will Pharvaris (PHVS) present its deucrictibant clinical data in 2025?

Pharvaris will present at three conferences: the C1-Inhibitor Workshop in Budapest (May 29-June 1), Eastern Allergy Conference in Palm Beach (May 29-June 1), and EAACI Congress in Glasgow (June 13-16, 2025).

What are the key findings from Pharvaris' CHAPTER-1 and RAPIDe-2 extension studies?

The presentations will cover long-term safety and efficacy data of oral deucrictibant for both prophylaxis and treatment of HAE attacks, including improvements in health-related quality of life and disease control in participants.

Where can investors access Pharvaris' (PHVS) presentation materials from the 2025 conferences?

The posters and presentation slides will be available on the Investors section of the Pharvaris website (https://ir.pharvaris.com/news-events/events-presentations) at the beginning of each respective presentation.